Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “JS001”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02915432
What this trial is testing

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Who this might be right for
Gastric AdenocarcinomaEsophageal Squamous Cell CarcinomaNasopharyngeal Carcinoma+1 more
Shanghai Junshi Bioscience Co., Ltd. 401
Large-scale testing (Phase 3)Study completedNCT04723004
What this trial is testing

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)
Shanghai Junshi Bioscience Co., Ltd. 326
Testing effectiveness (Phase 2)Looking for participantsNCT05173246
What this trial is testing

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Who this might be right for
Esophageal Small Cell Carcinoma
Sun Yat-sen University 43
Large-scale testing (Phase 3)Active Not RecruitingNCT06505837
What this trial is testing

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Who this might be right for
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 395
Testing effectiveness (Phase 2)UnknownNCT03951597
What this trial is testing

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma, Intrahepatic
Shanghai Zhongshan Hospital 30
Large-scale testing (Phase 3)Study completedNCT03829969
What this trial is testing

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Who this might be right for
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Shanghai Junshi Bioscience Co., Ltd. 514
Testing effectiveness (Phase 2)Study completedNCT04856631
What this trial is testing

Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Who this might be right for
Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd. 88
Early research (Phase 1)Study completedNCT04991506
What this trial is testing

ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorNeoplasmsMalignant Tumor
Elpiscience Biopharma, Ltd. 30
Testing effectiveness (Phase 2)Ended earlyNCT04603040
What this trial is testing

Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Who this might be right for
Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy
Shanghai Junshi Bioscience Co., Ltd. 17
Testing effectiveness (Phase 2)Looking for participantsNCT06791070
What this trial is testing

RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum

Who this might be right for
Paget Disease, ExtramammaryScrotum Disease
Fujian Medical University Union Hospital 20
Testing effectiveness (Phase 2)UnknownNCT04459663
What this trial is testing

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Who this might be right for
Non-small Cell Lung Cancer
Li Zhang, MD 50
Early research (Phase 1)Study completedNCT03167853
What this trial is testing

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Testing effectiveness (Phase 2)UnknownNCT04421469
What this trial is testing

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Who this might be right for
Nasopharyngeal Carcinoma
Fujian Cancer Hospital 39
Testing effectiveness (Phase 2)Ended earlyNCT03178123
What this trial is testing

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Who this might be right for
Mucosal Melanoma
Shanghai Junshi Bioscience Co., Ltd. 6
Early research (Phase 1)Ended earlyNCT05128539
What this trial is testing

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd. 9
Large-scale testing (Phase 3)Active Not RecruitingNCT04848753
What this trial is testing

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Who this might be right for
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd. 663
Early research (Phase 1)Study completedNCT03301688
What this trial is testing

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 38
Early research (Phase 1)UnknownNCT04206358
What this trial is testing

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Who this might be right for
Melanoma
Peking University Cancer Hospital & Institute 30
Early research (Phase 1)UnknownNCT03251313
What this trial is testing

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Who this might be right for
Triple Negative Breast Cancer
Fudan University 31
Testing effectiveness (Phase 2)UnknownNCT04316351
What this trial is testing

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Guangzhou Institute of Respiratory Disease 60
Next Page